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Background: We encountered a 5-year-old girl who had short-lasting, severe, unilateral temporal headaches with
ipsilateral lacrimation, nasal congestion and rhinorrhoea, and facial flushing after severe attacks. Family history
revealed similar short-lasting, severe headaches in an older brother, younger sister, mother, maternal aunt, and
maternal grandfather’s brother.
Methods: We performed routine laboratory examinations and electrophysiological and radiological studies for
three children, and whole-exome sequencing to determine the genetic causality in this family.
Results: Focal hyperperfusion of the right trigeminal root entry zone was seen during a right-sided attack in
one child, while left-sided temporal headache attacks were provoked by bilateral electrical stimulation of the
upper extremities in another. We identified a novel SCN9A mutation (NM_002977: c.5218G>C, p.Val1740Leu) in
all affected family members, but not in any of the unaffected members. SCN9A encodes the voltage-gated
sodium-channel type IX alpha subunit known as Nav1.7.
Conclusions: Gain-of-function mutations in Nav1.7 are well known to cause paroxysmal extreme pain disorder
(PEPD), a painful Na-channelopathy characterized by attacks of excruciating deep burning pain in the rectal,
ocular, or jaw areas. The SCN9A mutation suggests that our patients had a phenotype of PEPD with a predominant
symptom of short-lasting, severe, unilateral headache.
Keywords: Unilateral headache; Facial flushing; SCN9A mutation; Paroxysmal extreme pain disorder; Voltage-gated
sodium channel; Focal hyperperfusionBackground
Paroxysmal extreme pain disorder (PEPD) was first de-
scribed in 1959 as a familial disorder characterized by
very brief episodes of excruciating rectal pain associated
with flushing of the buttocks and legs, ocular pain and
flushing of the eyelid and periorbital skin, and submaxillary
pain [1]. In PEPD, autonomic symptoms of skin flushing,
often with a harlequin pattern distribution, emerge during
the neonatal period. Dramatic syncopes with bradycardia* Correspondence: neurologyimai@gmail.com; naomat@yokohama-cu.ac.jp
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in any medium, provided the original work is pand sometimes asystole are also common. Attacks of excru-
ciating deep burning pain in the rectal, ocular, or jaw areas
emerge later in affected individuals. These attacks are trig-
gered by factors such as defecation, cold wind, eating, and
emotions. These painful symptoms are completely allevi-
ated by carbamazepine in most patients [2].
SCN9A encodes the voltage-gated sodium-channel
type IX alpha subunit known as Nav1.7, which is mainly
expressed in peripheral sensory neurons of the dorsal
root/sympathetic ganglia. Mutations in this gene can cause
variable phenotypes with different patterns of inheritance.
Gain-of-function mutations mainly cause primary eryther-
malgia [3], PEPD [2], small-fiber neuropathy [4], and
chronic non-paroxysmal neuropathic pain [5] in an
autosomal-dominant manner. SCN9A mutations also resultOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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sions [7]. In addition, loss-of-function mutations in SCN9A
can lead to indifference to pain [8,9] and hereditary sensory
and autonomic neuropathy type IID [10] with autosomal-
recessive inheritance.
Here, we describe familial cases of a painful disorder
showing some clinical features reminiscent of those in
PEPD, but with short-lasting, severe, unilateral headache
over the cranium as the prominent symptom in most af-
fected family members. We identified a novel SCN9A
mutation in this family, suggesting that the family suffers
from a variant of PEPD. Detailed clinical information of
the proband and her siblings, and genetic data of her




The index patient (Patient 1: IV-3 in Figure 1) was a 5-
year-old girl with a history of recurrent, unilateral temporal
headaches lasting 20–90 s associated with ipsilateral con-
junctival injection, lacrimation, nasal congestion, rhinor-
rhea, and facial flushing. Headaches were often triggered
by hitting her head or body, taking a bath, experiencing a
temperature change, or sleeping. Her past medical history
included a febrile convulsion at 15 months old. She experi-
enced the first episode of severe headache with thrashing
and crying out at 16 months old. Thereafter, the frequency
of moderate or severe headache attacks gradually increased
to 10–20 times per day. Attacks initially emerged during
sleep, but later predominantly occurred during the daytime
while the patient was awake. When experiencing a severe
attack, she screamed and thrashed, and bilateral lacrima-
tion and facial flushing occurred (Additional file 1: VideoFigure 1 Familial pedigree. Autosomal-dominant inheritance is suspected.
presented for medical attention is shown.S1). Unilateral, mainly right-sided, facial and upper-
extremity flushing (Figure 2) appeared 5–10 min after
severe attacks and lasted from half an hour to a few
hours. She had undergone repeated medical examina-
tions, such as routine laboratory investigations, brain
computed tomography, magnetic resonance imaging
(MRI), and electroencephalography (EEG), but no or-
ganic abnormalities had been identified, and she had
received no medical treatment.
When the patient sought medical attention from our
institution, we tentatively diagnosed short-lasting unilateral
neuralgiform headache attacks with cranial autonomic
symptoms (SUNA), in accordance with the criteria of the
International Classification of Headache Disorders [11].
After initiation of treatment with carbamazepine at 50 mg/
day (3.125 mg/kg/day) at bedtime, the frequency and
intensity of attacks decreased within a couple of weeks,
and no adverse drug reactions were seen. An increase
in the carbamazepine dosage to 100 mg/day resulted in
complete disappearance of the attacks within 2 weeks.
When her parents forgot to give her the carbamazepine,
the attacks began again.
Family history revealed similar headaches with auto-
nomic symptoms in an older brother (Patient 3: IV-2), a
younger sister (Patient 2: IV-4), her mother (III-2), her
maternal aunt (III-4), and her maternal grandfather’s
brother (II-3). The headache attacks of her mother,
maternal aunt, and maternal grandfather’s brother all
showed spontaneous remission in adulthood. The aunt
has experienced episodic burning pain in the legs since
adolescence. The maternal grandfather had suffered epi-
lepsy and headache attacks with conjunctival injection.
Autosomal-dominant inheritance of this disease was in-
ferred from the pedigree (Figure 1).y, years. For each family member, age at the time Patient 1 first
Figure 2 Clinical findings. Flushing of (A) the face and (B) arm after
a right-sided severe headache attack in Patient 1.
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Headaches with similar features to those in her sister
emerged at 18 months old and were accompanied by
hemi-facial flushing after the severe headache attacks.
She had the same triggers as her sister, and in addition,
her headaches were often precipitated by defecation and
associated with external genital pain. She was treated
with carbamazepine at 35 mg/day (3.2 mg/kg/day at
bedtime), but this treatment showed little effect. After
the dosage of carbamazepine was increased to 50 mg/
day, the frequency of attacks decreased from 10–20
times per day to 1–2 times per day.
Patient 3 (IV-2)
Headaches had appeared at 2 years old and were accom-
panied by hemi-facial flushing after severe attacks. At
3 years old, headaches sometimes occurred during
defecation, along with enlargement and pain of the penis.
At 5 years old, the frequency of headaches had increased to
1–2 times per week. The patient’s mother did not remem-
ber the frequency of headaches before 5 years old, because
his headache attacks were less frequent and severe than
those of the proband. His headache attacks were able to be
prevented with carbamazepine at 100 mg/day.
Patient 4 (III-2)
She had experienced moderate to severe unilateral
headaches since childhood, associated with ipsilateral
conjunctival injection and flushing that lasted 1–2 min
several times a year. Headaches occurred frequently
around 3 to 5 years old, similar to those in her children.
In addition to headache attacks, moderate burning pain
in her legs occasionally occurred during defecation. She
also had scoliosis.Patient 5 (III-4)
She had experienced moderate unilateral headaches with
ipsilateral conjunctival injection since childhood. Genital
pain sometimes occurred during defecation, with enlarge-
ment of the external genitalia. She had chronic pain in her
extremities that emerged in childhood and worsened in the
lower limbs when she was a high school student. Severe
pain was occasionally provoked by light touch and warm-
ing, and was relieved by cooling.Patient 6 (II-3)
Patient 6, a younger brother of the maternal grandfather
of Patients 1–3, had moderate to severe unilateral head-
aches with ipsilateral conjunctival injection in childhood.
He did not remember any further detailed features con-
cerning the headaches.Methods
In an attempt to identify the background condition of
the painful disorder and to find any structural or func-
tional abnormalities in the central and peripheral nervous
systems of the family members, Patients 1–3 were admit-
ted for further evaluation. We observed and recorded all
headache attacks of the three patients in the hospital for
3 days. We also performed routine laboratory examin-
ation, spinal radiography, brain MRI, brain magnetic res-
onance angiography, and nerve conduction studies in all
patients. Patients 1 and 2 underwent a 3-day period of
video-EEG monitoring. Patient 3 underwent routine EEG,
as well as examination of somatosensory evoked poten-
tials. Brain MRI examinations were performed with 3.0-T
scanners (Siemens Magnetom Verio, Munich, Berlin and
Erlangen, Germany: Patients 1 and 3; Philips Achieva,
Amsterdam, the Netherlands: Patient 2). Cervical and
thoracic MRI was performed in Patient 2. We conducted
interictal single photon emission computed tomography
(SPECT) scans with 99mTc-ethyl cysteinate dimer in Pa-
tients 1 and 2. Ictal SPECT of Patient 2, whose headaches
were the most frequent among the siblings, was also
successfully performed. The subtraction ictal SPECT
co-registered to MRI (SISCOM), which improves the
sensitivity and specificity of SPECT under paroxysmal
conditions [12,13], was performed using a previously
reported method [14]. To identify the genetic causation
in this pedigree, WES and WES-based linkage analysis
were performed using DNA from nine family members
(the individuals with asterisks in Figure 1: six affected
and three unaffected family members) based on an
autosomal-dominant model of inheritance. Detailed
methods are described in the Supplementary methods.
We considered that Patient II-1 possessed a heterozy-
gous mutation with incomplete penetrance.
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consent
This study conformed to the ethical standards described
in the Declaration of Helsinki and was approved by the
institutional review boards at both Japanese Red Cross
Shizuoka Hospital and Yokohama City University School
of Medicine. The parents of the patient 1, 2 and 3 pro-
vided written informed consent and the authorization to
publish any photos or videos of recognizable persons.
Results
Upon examination, general and neurological findings
were unremarkable other than a tendency toward hypor-
eflexia in the three subjects. The clinical features of
these patients are summarized in Table 1.
Video-EEG monitoring recorded 19 attacks each in
Patients 1 and 2 and demonstrated no ictal EEG changes
during the headache attacks. Spinal X-rays revealed
scoliosis in Patient 3, but not in Patients 1 and 2. All pa-
tients showed normal results from nerve conduction
studies. Routine laboratory examination, head MRI, and
head magnetic resonance angiography were normal in
all cases. In Patient 1, MRI of the cervical and thoracicTable 1 Clinical findings in our study of three cases with shor
Patient 1, Pa
Female Fe
Severity of the pain Moderate or severe Mo
Location of the pain Unilateral, mainly left-sided forehead,




Duration of attacks 20-90 s 20
Frequency of attacks during
the 3 days of admission
19 times; 17 times during sleep, and four
times during the daytime nap.
19
Ipsilateral autonomic features
Conjunctival injection + ?*
Lacrimation + +
Nasal congestion + +
Rhinorrhea + +
Eyelid edema - -
Forehead and facial sweating - -
Forehead and facial flushing + +






Premonitory features or auras None No
*We could not observe this feature because of tight closing of her eyes.
†We observed bilateral lacrimation.
‡We observed hemifacial edema.
∏ We observed contralateral miosis one time.spine was performed in an attempt to identify sympa-
thetic nerve lesions leading to facial flushing, but yielded
normal results. Unexpectedly, stimulation of the median
nerves (5 Hz, 500 counts) to assess somatosensory
evoked potentials provoked left-sided temporal headache
attacks in Patient 3. SISCOM analysis demonstrated focal
hyperperfusion of the right trigeminal root entry zone dur-
ing a right-sided attack in Patient 2 (Figure 3). Interictal
SPECT images from Patient 1 were unremarkable.
WES identified a heterozygous missense mutation
(c.5218G>C, p.Val1740Leu) in SCN9A (NM_002977)
in all affected family members, but not in any of the
unaffected members (Additional file 2: Tables S1 &
S2). This variant was confirmed with Sanger sequen-
cing (Figure 4A). SCN9A is located on chromosome 2
within the linked region spanning 7.3 Mb, and showed a
maximum logarithm of the odds score of 1.805 (Additional
file 2: Table S3, Additional file 2: Figure S1). The altered
amino acid (p.Val1740) is highly evolutionally conserved
from lampreys to humans (Figure 4B). Based on the
SMART program (http://smart.embl-heidelberg.de/) and
UniProt KB (http://www.uniprot.org/uniprot/), p.Val1740
was located in the transmembrane region of the polycystict-lasting trigeminal autonomic cephalalgia
tient 2, Patient 3,
male Male




At the beginning bilateral orbital pain, immediately
changed to ipsilateral frontal and temporal
headache, mainly right-sided














Figure 3 SPECT co-registered to MRI (SISCOM) analysis in Patient 2. A) Transverse, B) sagittal, and C) coronal images. A focal increase in perfusion
is noted at the right trigeminal root entry zone during a right-sided attack.
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S2). This missense mutation was predicted to be pathogenic
according to the in silico programs SIFT: 0, Polyphen-2:
0.883, and MutationTaster: 0.97471. Next, we evaluated the
effects of the mutation on protein structures at the molecu-
lar structural level using an in silico model [15]. The human
sodium channel Nav1.7 encoded by SCN9A consists of a
long polypeptide that folds into four homologous domains
(domains I-IV). Because the overall architecture of Nav1.7
and other voltage-gated ion channels is considered to be
similar, we mapped the identified mutation on the available
high-resolution structure of a sodium channel from Arco-
bacter butzleri (NavAb) (PDB code 3rvz) (Figure 5). Val
1740, which corresponds to Met 209 of NavAb as deter-
mined from amino acid alignment, is predicted to be lo-
cated within the S6 segment of domain IV and in the
hydrophobic core, suggesting a potential impact of the
Val1740Leu mutation on Nav1.7 function.
Discussion
Patient 1 was initially diagnosed with SUNA based on
the symptoms of unilateral temporal headaches lasting
20–90 s in association with cranial autonomic symp-
toms. However, harlequin-type flushing and pain of the
external genitalia accompanied headache in some of her
relatives, representing a quite unusual occurrence in
SUNA. The p.Val1740Leu mutation in SCN9A, identified
in all affected family members, but not in any unaffected
members, suggested that the clinical condition in this
family may be regarded as a novel variant of PEPD.Although headaches not localized to the orbital and
submaxillary areas have not been reported in PEPD,
the unusual aspects of headache-associated phenom-
ena were reminiscent of those in PEPD.
SISCOM findings from a patient in the present family
support the idea that augmented excitation of the tri-
geminal nerve is essential for the emergence of headaches
in certain cases of short-lasting, unilateral headaches. Func-
tional MRI studies have revealed functional changes in the
nervous systems accompanying similar short-lasting, unilat-
eral headaches in the trigeminal areas as follows: activation
of the red nucleus, ventral pons, trigeminal root entry zone,
and hypothalamus ipsilateral to the pain side in subjects
with cluster headache [16], activation in the region of the
ipsilateral hypothalamic gray matter in short-lasting unilat-
eral neuralgiform headache attacks with conjunctival injec-
tion and tearing (SUNCT) [17], and bilateral hypothalamic
activation during the pain attacks in a SUNCT patient [18].
This last patient became completely pain-free after surgical
decompression of the ipsilateral trigeminal nerve. We hy-
pothesized that a peripheral trigger with ectopic excitation
may have contributed to the clinical picture of SUNCT in
this patient. In addition, SPECT images of two patients with
SUNA showed normal tracer uptake and symmetric perfu-
sion during headache episodes [19]. The hyperperfusion ob-
served at the trigeminal root entry zone in this study may
support the trigeminovascular theory for the pathogenesis
of migraines and trigeminal autonomic cephalalgia, assum-
ing a primary pathological activation of trigeminal ganglion
cells and resultant antidromic pain generation through
Figure 4 (See legend on next page.)
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Figure 4 Genetic analysis of the pedigree. Electropherograms of the heterozygous SCN9A mutation. Arrow indicates the position of the mutation
(NM_002977: c.5218G>C, p.Val1740Leu). Data from six affected and three unaffected individuals are shown on the left and right panels,
respectively. A G/C change is represented as an “S” according to the IUPAC code. B) Evolutionary conservation of p.Val1740 in SCN9A from
lampreys to humans. The altered amino acid residue is marked with a red box. The degree of evolutionary conservation was scored by Genomic
Evolutionary Rate Profiling. C) The upper portion illustrates the SCN9A protein with functional domains predicted by the SMART program using
the protein sequence (NP_002968). Ion trans, ion transport domain; DUF3451, DUF3451 domain; Na trans, sodium ion transport-associated domain; PDB,
PDB domain; PKD, PKD (polycystic kidney) channel domain; IQ, IQ motif (calmodulin-binding motif). Middle and lower portions indicate the location of
human SCN9A mutations: red double circles, mutation identified in this pedigree; red open circles, erythermalgia; red filled circles, PEPD; red open squares,
pain; dysautonomia and acromesomelia; red filled squares, chronic non-paroxysmal neuropathic pain; blue open circles, small fiber neuropathy; blue open
square, hereditary sensory and autonomic neuropathy type IID; blue filled circles, indifference to pain; black open circles, febrile convulsion; black filled
circles, Dravet syndrome. *The patient with p.A1632E showed both erythromelalgia and PEPD [21].
Imai et al. The Journal of Headache and Pain  (2015) 16:35 Page 7 of 9neuropeptide release at the vessel walls. The provocation of
headache by repetitive stimulation of somatosensory af-
ferents is important, because cluster-like attacks can be
provoked in cluster headache patients by experimental
low-frequency stimulation of the sphenopalatine gan-
glion at 5 Hz [20]. This phenomenon may be related to
aberrant Nav1.7 function, and the possibility of a role
for mutant SCN9A in the scheme of trigeminovascular
theory requires further study.
Lastly, it is interesting that the mutations causing
PEPD are mostly located on the C-terminal half of theA
B
Figure 5 Structural implications of the mutated SCN9A gene product. A) Multi
segments in domain IV from human Nav1.2, 1.5, and 1.7 with the S6 pore-lining
channel from Arcobacter butzleri (NavAb) (PDB code 3rvz) [15] viewed from the
identified mutant position indicated.SCN9 protein, as commonly seen in the present family,
whereas those related to Dravet syndrome/febrile con-
vulsions are located on the N-terminal half (Figure 4C).
Differential impact from the site of SCN9A mutations on
the function in peripheral pain control and excitation of
cortical neurons is assumed.
Conclusions
A novel SCN9A mutation was found in a pedigree in
which affected family members suffered from short-
lasting, severe, unilateral temporal headaches characterizedple alignment of amino acid sequences from the S6 transmembrane
segment from NavAb [15]. B) Crystal structure of a voltage-gated sodium
intracellular side of the membrane (left) and from the side (right), with the
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aches were associated with pain of the external genitalia,
harlequin-type facial flushing after headache events, as well
as paroxysmal, burning limb, pain in some subjects. The
SCN9A mutation in this family suggests that the phenotype
of the patients represents an unusual variant of PEPD. This
report expands on the clinical spectrum of SCN9A-related
painful disorders, and supports the essential role of aber-
rant peripheral activation in the pathogenesis of trigeminal
nerve-related, short-lasting, primary headaches.
Additional files
Additional file 1: Video S1. Headache attack of Patient 2. The video
was taken by the patient’s mother just after the beginning of a severe
headache attack. The patient screams and thrashes, and bilateral
lacrimation and facial flushing are observed. The attack lasted for 1
minute.
Additional file 2: Methods, linkage analysis, tables and figures.
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